BLU-667 | Friends of Cancer Research

You are here

BLU-667

Sponsor: 
Blueprint Medicines Corporation
Indication: 
Patients with RET fusion-positive NSCLC that has progressed on platinum-based chemotherapy
Category: 
Year: 
2019
Date: 
Feb 26th
FDA Status: 
Designation Granted